Gene · 25913
NIH grants1,830
NIH grants whose papers are about the gene, through NIH's grant-paper links.
1,001 to 1,020 of 1,830
Download this page as JSON| Grant | Title | POT1 papers | Newest fiscal year |
|---|---|---|---|
| R01NS080820 | Gene discovery in PSP by transcriptome, neuropathology and sequence analysis | 1 | 2017 |
| R01NS082240 | Role of DNA damage in the early steps of HSV infection and latency in neurons | 1 | 2017 |
| R01NS082311 | Mechanisms of glioma growth and invasion novel therapeutic strategies | 1 | 2017 |
| R15GM124650 | Novel Functions of LAMMER-related Kinases in Gene Expression | 1 | 2017 |
| R21CA187388 | Validation of FOXM1 as a new therapeutic target in high-risk myeloma | 1 | 2017 |
| R21CA191856 | The Ape1-NPM1 Axis and Telomere Maintenance | 1 | 2017 |
| R21CA205778 | Statistical Detection and Biochemical Classification of Cancer Driver Mutation Patterns in Biological Networks | 1 | 2017 |
| R37HD045022 | In Vitro Reprogramming of Somatic Cells into Pluripotent ES-like Cells | 1 | 2017 |
| RF1AG057519 | Genomic and Biological Studies of APOE ε2 in Alzheimer Disease | 1 | 2017 |
| RF1AG058267 | Characterization of Rapidly Progressive Alzheimer's Disease | 1 | 2017 |
| T32AG000216 | Training in the Neuroplasticity of Aging | 1 | 2017 |
| T32CA177555 | Molecular Pathology of Cancer | 1 | 2017 |
| U01AG049505 | CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample | 1 | 2017 |
| U01AG049506 | Sequence-based Discovery of AD Risk & Protective Alleles | 1 | 2017 |
| U01AG049507 | Sequence-based Discovery of AD Risk & Protective Alleles | 1 | 2017 |
| U01AG049508 | Modifier Genes that Influence Age at Onset or Protect Against Development of Alzheimer's Disease (AD) | 1 | 2017 |
| U01HL117721 | Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease | 1 | 2017 |
| U41HG001715 | A human binary interactome reference map by 2020 | 1 | 2017 |
| UL1TR001070 | The Ohio State University Center for clinical and Translational Science | 1 | 2017 |
| UL1TR001079 | Institute for Clinical and Translational Research | 1 | 2017 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25913/grants?page=51